Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection Steven L. Flamm, Eric Lawitz, Ira Jacobson, Marc Bourlière, Christophe Hezode, John M. Vierling, Bruce R. Bacon, Claus Niederau, Morris Sherman, Venkata Goteti, Heather L. Sings, Richard O. Barnard, John A. Howe, Lisa D. Pedicone, Margaret H. Burroughs, Clifford A. Brass, Janice K. Albrecht, Fred Poordad Clinical Gastroenterology and Hepatology Volume 11, Issue 1, Pages 81-87.e4 (January 2013) DOI: 10.1016/j.cgh.2012.10.006 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Study design. Clinical Gastroenterology and Hepatology 2013 11, 81-87.e4DOI: (10.1016/j.cgh.2012.10.006) Copyright © 2013 AGA Institute Terms and Conditions
Figure 2 Patients with SVR, according to treatment group and analysis. Clinical Gastroenterology and Hepatology 2013 11, 81-87.e4DOI: (10.1016/j.cgh.2012.10.006) Copyright © 2013 AGA Institute Terms and Conditions
Supplementary Figure 1 Randomization, end-of-treatment response, and SVR among the study population. Clinical Gastroenterology and Hepatology 2013 11, 81-87.e4DOI: (10.1016/j.cgh.2012.10.006) Copyright © 2013 AGA Institute Terms and Conditions